# Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

> **NCT03249714** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Matching placebo of ofatumumab

## Key facts

- **NCT ID:** NCT03249714
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2019-12-26
- **Final completion:** 2020-07-29
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03249714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03249714, "Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03249714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*